NCT06650748 2026-03-17
NeoMARS
Peking University
Phase 2 Enrolling by invitation
Clinical Trials
35 trialsNCT07441369 2026-03-02
Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer
Fudan University
Phase 2 Enrolling by invitation
NCT06250777 2026-02-09
ELPIS
Yonsei University
Phase 2 Enrolling by invitation
NCT07386704 2026-02-04
Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
Peking University First Hospital
Phase 2 Enrolling by invitation
NCT07363031 2026-01-23
Oral Herpesviruses and Oral Mucositis in Patients Receiving Head and Neck Radiotherapy
Instituto Oncoclinicas
Phase 2 Enrolling by invitation
NCT07359404 2026-01-22
Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Enrolling by invitation
NCT07344220 2026-01-15
DZ-002-201
Hoag Memorial Hospital Presbyterian
Phase 2 Enrolling by invitation
NCT07139951 2025-12-31
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for the Treatment of Patients With Gastric and Gastroesophageal Junction Adenocarcinoma at High Risk of Peritoneal Recurrence
Mayo Clinic
Phase 2 Enrolling by invitation
NCT07312578 2025-12-31
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Enrolling by invitation
NCT07310069 2025-12-30
TRANSFORM-GBC
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Enrolling by invitation
NCT07275463 2025-12-22
[99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression
Tomsk National Research Medical Center of the Russian Academy of Sciences
Phase 2 Enrolling by invitation
NCT06843681 2025-11-28
Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Enrolling by invitation
NCT06723015 2025-11-18
Tau PET Outcomes With Anti-amyloid Immunotherapies
Mayo Clinic
Phase 2 Enrolling by invitation
NCT06680596 2025-09-22
SAFIR3LibHERty
UNICANCER
Phase 2 Enrolling by invitation
NCT07167459 2025-09-11
Personalized SBRT in Early-Stage Peripheral NSCLC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Enrolling by invitation
NCT07130149 2025-08-19
Sonodynamic-Chemoradiotherapy Integration in Glioblastoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Enrolling by invitation
NCT07101900 2025-08-08
68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses
Peking Union Medical College Hospital
Phase 2 Enrolling by invitation
NCT06688175 2025-08-07
IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma
The First Affiliated Hospital of Xiamen University
Phase 2 Enrolling by invitation
NCT06054178 2025-07-28
Identification of Nerves Using Fluorescein Sodium
Stanford University
Phase 2 Enrolling by invitation
NCT06999148 2025-05-31
Study on The Sensitizing Effect of Sonodynamic Therapy on The Treatment of Brainstem Glioma With Radiotherapy and Chemotherapy and Survival Analysis
The First Affiliated Hospital of Zhengzhou University
Phase 2 Enrolling by invitation
NCT06419179 2025-05-20
GUIDANCE
University of Cologne
Phase 2 Enrolling by invitation
NCT06963060 2025-05-08
GALENT-BT
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Enrolling by invitation
NCT02646839 2025-05-04
KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children
Pediatric Transplantation & Cellular Therapy Consortium
Phase 2 Enrolling by invitation
NCT06931613 2025-04-17
Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment
St. Petersburg State Pavlov Medical University
Phase 2 Enrolling by invitation
NCT06901622 2025-03-30
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Enrolling by invitation
NCT06816966 2025-02-10
CISART
Fujian Medical University Union Hospital
Phase 2 Enrolling by invitation
NCT06664970 2024-10-30
A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor
Peking Union Medical College Hospital
Phase 2 Enrolling by invitation
NCT05170919 2024-09-19
Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients with Advanced Stage Cancer
Englewood Hospital and Medical Center
Phase 2 Enrolling by invitation
NCT06487715 2024-07-05
Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Enrolling by invitation
NCT06481956 2024-07-01
T-DM1 Combined With CDK4/6 Inhibitor Ribociclib
Zhejiang Cancer Hospital
Phase 2 Enrolling by invitation
NCT05396118 2024-05-14
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
Rigshospitalet, Denmark
Phase 2 Enrolling by invitation
NCT05576389 2022-11-15
Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer
Peking University People's Hospital
Phase 2 Enrolling by invitation
NCT05171335 2022-09-21
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients
The Methodist Hospital Research Institute
Phase 2 Enrolling by invitation
NCT04361370 2021-04-19
OPEB-01
Yonsei University
Phase 2 Enrolling by invitation
NCT03827616 2019-02-12
Moderately Hypofractionated Radiotherapy for Prostate Cancer.
Tatarstan Cancer Center
Phase 2 Enrolling by invitation